To evaluate the efficacy of quinazolinone-thiazolidinedione hybrids as selective EGFR inhibitors in treating lung cancer.
Synthesis of new quinazolinone-thiazolidinedione hybrids
Evaluation of anti-lung cancer activity
Testing selectivity for EGFR inhibition
Compound 9 emerged as a promising candidate for EGFR-targeted therapy
Demonstrated selective inhibition of EGFR in lung cancer cells
Encouraging potential for further optimization in clinical applications
Resumen
These findings indicate that the synthesized hybrids, particularly compound 9, represent promising leads for selective EGFR-targeted lung cancer therapy and support further optimization.